Table 1 Baseline characteristics of patients with a diagnosis of MGUS and SMM at first sample collection.

From: Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients

 

MGUS (n = 99)

SMM (n = 184)

Female - n(%)

47 (47)

82 (45)

Median age - years (IQR)

68 (58–75)

64 (55–71)

Median percentage bone marrow plasma cells - n(IQR)

5 (3–9)a

20 (15–30)

Median hemoglobin - g/dL (IQR)

13.2 (12.3–14.3)

12.5 (11.4–13.7)

Median creatinine - mg/dL (IQR)

1.1 (0.9–1.4)

1.1 (0.9–1.3)

Median MCP - g/dL (IQR)

0.5 (0–1.4)

2.1 (1.4–2.9)

Median iFLC - mg/dL (IQR)

3.5 (2–11.9)

6.45 (2.8–20.3)

Evaluable for risk stagingb – n

79

137

 0 risk factors - n(%)

19 (24)

43 (31)

 1 risk factor - n(%)

24 (30)

36 (26)

 2 risk factors - n(%)

34 (43)

41 (30)

 3 risk factors - n(%)

2 (3)

17 (13)

Heavy chain isotype

 IgG - n(%)

52 (53)

138 (75)

 IgA - n(%)

29 (29)

40 (22)

 Otherc - n(%)

18 (18)

6 (3)

Light chain

 Kappa - n(%)

58 (59)

127 (69)

 Lambda - n(%)

41 (41)

57 (31)

Median time between diagnosis and first sBCMA collection - months (IQR)

0 (0–6.5)

1.9 (0–7.6)

Median sBCMA at first sample collection (IQR)

77.3 (37.9–128.8)

128 (77.4–212)

  1. aBaseline bone marrow biopsy results were available for 25 MGUS patients
  2. bRisk factors for MGUS patients include a monoclonal protein ≥1.5 g/dL, an abnormal free light chain ratio, and a non-IgG monoclonal protein isotype [26]. Risk factors for SMM patients include a baseline bone marrow plasma cell percentage >20%, serum free light chain ratio >20, and baseline monoclonal protein >2 g/dL [14].
  3. cIncludes light chain, IgD, and IgM isotypes.
Back to article page